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Abstract
There is a growing evidence that allergen immunotherapy (AIT) can provide significant and long-
lasting clinical benefit for a number of allergic individuals. However, it is less clear if AIT results 
in clinical tolerance, which is characterized by a persistent state of clinical non-reactivity to 
allergens after therapy is finished. Addressing this knowledge gap is particularly relevant for 
patients undergoing AIT for food allergies, as anything less than complete tolerance could have 
potentially devastating consequences. An increasing number of studies, in particular those 
involving oral immunotherapy, are attempting to assess tolerance induction following AIT. 
Clinical tolerance does appear to be achievable in a subset of patients undergoing AIT, but 
whether this is equivalent to the type of tolerance observed in nonallergic individuals remains 
unknown. Developing established criteria for assessing tolerance induction, as well as the use of 
consistent terminology when describing clinical tolerance, will be important for determining the 
disease-modifying potential of AIT.
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Introduction
Allergen immunotherapy (AIT) is a potentially disease-altering treatment for atopic 
disorders. Since its initial description over 100 years ago, AIT remains an important 
therapeutic option for patients suffering from allergic rhinitis, allergic conjunctivitis, 
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allergen-driven asthma, and insect sting allergy [1]. AIT involves giving an allergen to IgE-
sensitized individuals in increasing amounts, with the goal of inducing clinical non-
responsiveness to the allergen. Subcutaneous immunotherapy (SCIT) has been used 
extensively for the treatment of allergen-driven respiratory diseases or stinging insect 
allergy, and its efficacy has been supported by several randomized trials [2–4]. Sublingual 
immunotherapy (SLIT) has also proven effective for the treatment of allergic rhinitis, 
primarily in patients allergic to pollens [5]. More recently, the use of oral immunotherapy 
(OIT) as a treatment for food allergies is being intensely researched [6]. Novel strategies for 
AIT, including intralymphatic or epicutaneous immunotherapy, are also under current 
investigation [7]. While AIT is frequently described as a potentially curative treatment for 
allergic disorders, its ability to induce tolerance to allergens remains understudied. In this 
report, we will review the evidence for clinical tolerance in patients undergoing AIT.
What is tolerance?
Defining tolerance can be challenging, as the term has different meanings depending upon 
the scientific or clinical discipline (Table 1). From the perspective of basic immunology, 
tolerance refers to a state of unresponsiveness of the adaptive immune system to a specific 
antigen. Immunological tolerance is an active process and involves either deletion, 
inactivation, or suppression of antigen-specific lymphocytes in central lymphoid organs or 
peripheral tissues [8]. The development of immunological tolerance is not only important for 
preventing autoimmunity, but also for averting maladaptive immune responses against 
innocuous environmental allergens or commensal microorganisms. In the field of clinical 
allergy, the term tolerance pertains to a lack of clinical reactivity to an allergen. Clinical 
tolerance implies a state of unresponsiveness that persists regardless of allergen exposure. 
For example, a person who demonstrates tolerance to peanuts will not develop clinical 
symptoms upon ingestion, regardless of the frequency or the amount of consumption. This is 
in contrast to desensitization, which can be defined as a temporary state of clinical non-
reactivity that is dependent upon persistent allergen exposure. While clinical tolerance is 
generally thought to depend upon the establishment of immunological tolerance, the two 
processes may involve distinct mechanisms. For example, clinical tolerance may rely on 
modulation of both innate immune cells and lymphocytes [9], whereas the mechanisms of 
immunological tolerance involve only the adaptive immune system. For this review, we will 
use the term tolerance to be synonymous with clinical tolerance. As described below, 
clinical tolerance can develop naturally or be acquired through therapeutic intervention.
In the majority of individuals, clinical tolerance to allergens appears to occur naturally. How 
natural tolerance to allergens arises is incompletely understood and has been largely inferred 
from studies of patients undergoing AIT or exposed naturally to high-dose allergen, such as 
beekeepers and cat owners [10, 11]. Tolerance following high-dose allergen exposure has 
been suggested to result from the induction of interleukin (IL)-10-producing regulatory T 
cells (Treg) [12, 13] and the production of inhibitory allergen-specific IgG4 [14, 15]. 
However, it is possible that tolerance induction by low doses of allergen may involve 
different mechanisms, such as the extrathymic generation of Treg expressing the 
transcription factor forkhead box P3 (FOXP3) [16]. Furthermore, the immune pathways 
leading to tolerance may vary depending upon the site of allergen exposure. For example, 
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the immuno-suppressive cytokine transforming growth factor beta appears to be essential for 
tolerance induced at mucosal surfaces but not in the skin [12]. It is also noteworthy that 
natural tolerance can develop even after allergic sensitization has occurred. This is most 
evident in children with milk and egg allergies, who will frequently "outgrow" their allergies 
to these foods [17]. Why allergies naturally resolve in some individuals but not others is 
unclear, but may involve the induction of allergen-specific Treg and suppression of specific 
IgE production [18, 19].
When natural tolerance fails to develop, clinical tolerance may be acquired through 
therapeutic interventions, such as AIT. AIT involves the administration of increasing 
amounts of allergen, with the goal of reducing allergic symptoms upon natural allergen 
exposure. AIT can lead to allergen desensitization, which can occur within hours of 
initiating therapy [20]. However, desensitization is a temporary condition, as clinical 
responsiveness recurs once AIT is stopped. A more desirable outcome for AIT is induced 
tolerance, which refers to clinical unresponsiveness to allergens that persists after AIT is 
discontinued. Induced tolerance following AIT may not be equivalent to natural tolerance, 
as the mechanisms responsible for these conditions may be distinct. For example, induced 
tolerance during OIT is characterized by an increase in allergen-specific IgG4, whereas 
natural tolerance to egg has been associated with low IgG4 levels [21]. Furthermore, natural 
tolerance is generally thought to be permanent, whereas induced tolerance may wane with 
time [22]. Because of these differences, the term sustained unresponsiveness has been 
proposed as a more accurate description of the clinical non-reactivity observed after 
successful AIT in food allergic patients [23••].
Can tolerance be achieved with AIT?
There are a small but increasing number of studies demonstrating that patients may 
experience long-term clinical benefits after AIT is stopped, although the methodologies and 
criteria used for determining sustained efficacy are variable. Many studies use the term 
tolerance to describe the long-term clinical efficacy of AIT. However, the definition of 
"longterm" appears to vary widely among studies, ranging anywhere from a year to over a 
decade. Tolerance is also frequently used to describe a reduction in symptomology upon 
allergen exposure, rather than a complete absence of clinical reactivity. While decreased 
symptoms may be an adequate outcome of AIT for a person with allergic rhinitis, it is likely 
unacceptable for someone with food allergies. Overall, the induction of clinical tolerance 
following AIT likely depends upon multiple factors, including the age of the patient, the 
length of therapy, the type of allergic disease, the route of allergen delivery, and the allergen 
itself. Below, we will review the evidence of tolerance induction following AIT for different 
allergic diseases.
Food Allergy
It is arguable that the induction of clinical tolerance following AIT is most salient for 
patients with food allergies. A primary goal of food immunotherapy is for patients to 
consume the food following cessation of treatment. Anything less than complete clinical 
tolerance would potentially place the patient at risk for serious allergic reactions upon food 
ingestion. While it is clear that a majority of patients can be desensitized to food allergens 
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with OIT or SLIT, only a minority appear to develop induced tolerance (sustained 
unresponsiveness) [8]. The exact definition of sustained unresponsiveness is somewhat 
arbitrary, but generally refers to a lack of clinical reactivity to the ingested food for 1–6 
months following therapy.
Early uncontrolled studies provided hope that food allergic patients could develop clinical 
tolerance following OIT. In 2007, Buchanan et al. found that two of seven egg-allergic 
patients undergoing OIT developed clinical tolerance, which was defined as passing a 
double blind, placebo-controlled food challenge (DBPCFC) 3–4 months after stopping 
therapy [24]. A few years later, Vickery et al. evaluated tolerance induction in six children 
(ages 3–13 years) undergoing egg OIT using a conditionally increased dosing strategy based 
on egg white IgE levels. All six patients passed a DBPCFC 1 month after discontinuing 
therapy [25]. In 2012, Keet et al. assessed tolerance in milk-allergic subjects receiving either 
SLIT or OIT, with the OIT cohort further divided into either low- or high-maintenance 
dosing groups [26]. Only one often subjects receiving SLIT passed a DBPFC 6 weeks after 
therapy completion, compared to 8/20 in the OIT groups (3/10 in the low-dose group and 
5/10 in the high-dose group). However, in a follow-up study of five tolerant subjects from 
this trial, only three were regularly consuming milk when surveyed roughly 3 years after 
OIT [27•].
Only a few controlled trials have evaluated tolerance induction following food 
immunotherapy. In 2007, Staden et al. [28] investigated tolerance in 45 children with egg- or 
milk-allergy verified by food challenge. Subjects were randomized to either OIT or 
elimination diet for a median of 21 months. OIT was then discontinued for 2 months, and 
both groups underwent a DBPCFC. The OIT and elimination groups had similar pass rates 
(36 and 35 %, respectively), and therefore, it was unclear if tolerance had been induced by 
OIT or developed naturally. In 2012, a randomized, double-blind, placebo-controlled trial by 
the Consortium for Food Allergy Research (CoFAR) evaluated desensitization and sustained 
unresponsiveness in egg-allergic children randomized to either OIT (40 subjects) or placebo 
(15 subjects) [23••]. After 22 months of therapy, 75 % of the OIT group passed a DBPCFC 
and were considered desensitized. Conversely, no subjects from the placebo group passed a 
DBPCFC after 10 months of therapy. After discontinuing therapy for 4–6 weeks, 28 % of 
the OIT-treatment group passed another DBPCFC at 24 months and were labeled as having 
sustained unresponsiveness. These patients were instructed to add egg to their diet ad 
libitum and did not report any adverse effects when surveyed 12 months later. A limitation 
to this study was that no subjects from the placebo group were assessed for tolerance at 24 
months, although the likelihood of spontaneous resolution of egg allergy was extremely low 
for this patient cohort.
In a recent report by Vickery et al. [29•], sustained unresponsiveness was evaluated in a 
peanut-allergic cohort that had been previously desensitized with peanut OIT [30]. In this 
pilot study, 24 patients were treated for up to 5 years with peanut OIT at doses up to 4000 
mg of OIT/day All 24 patients became desensitized as determined by passing a DBPCFC 
with 5000 mg of peanut while on therapy. After discontinuing therapy for 4 weeks, 50 % of 
subjects passed another DBPCFC and were considered tolerant. Over a median follow-up 
period of 40 months, all but one of the tolerant patients was regularly consuming peanuts 
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with no adverse effects. Notably, the one tolerant patient who did not incorporate peanut 
into their diet experienced an increase in peanut-specific IgE and skin test wheal size, 
suggesting recurrence of their peanut allergy. While this study lacked a placebo-controlled 
comparison group, it is extremely unlikely that half of the subjects would have naturally 
developed tolerance during the trial. That same year, Syed et al. [31•] evaluated tolerance 
induction in a phase I study involving 23 peanut-allergic patients receiving peanut OIT or 20 
age-matched controls undergoing standard of care (peanut avoidance). After 24 months, 20 
of 23 OIT subjects passed a DBPCFC and were considered desensitized, whereas all control 
patients failed the challenge. After stopping therapy for 3 months, 7 of 20 patients passed a 
subsequent DBPCFC and were thus labeled as tolerant. However, when OIT was held for 
another 3 months (6 months total), only three patients remained clinically tolerant. 
Interestingly, the authors found that the methylation status of the FOXP3 gene promoter 
may predict which patients remain tolerant following OIT.
Some preliminary conclusions can be drawn from these studies. For one, clinical tolerance 
following OIT does develop, albeit in a minority of patients. About 25–50 % of OIT subjects 
demonstrate clinical tolerance when assessed within 1–3 months of discontinuing therapy. 
However, this percentage appears to decrease significantly when tolerance is assessed after 
longer periods of food allergen avoidance. This suggests that the clinical efficacy of OIT is 
generally transient, and that regular consumption of the allergen is necessary to maintain 
OIT-induced tolerance. This is clearly different than what is observed for individuals who 
are naturally tolerant to foods. It is also likely that the duration, dosage, and administration 
route of food immunotherapy will impact the likelihood of developing tolerance. The 
relatively high rate of sustained unresponsiveness observed by Vickery et al. may be related 
to the long duration of therapy (up to 5 years) and high dose of OIT (4000 mg). The higher 
doses achieved with OIT might explain its apparent superiority to SLIT for desensitizing 
patients and inducing sustained unresponsiveness [26, 32]. Finally, nearly all of these studies 
are limited by the lack of a control group during tolerance assessment. While observational 
studies would suggest that natural resolution of food allergy would be highly unlikely in the 
patient cohorts studied, this needs to be more rigorously addressed. In summary, while the 
few small studies to date are promising, larger placebo-controlled trials are necessary for 
accurately determining tolerance induction following food immunotherapy.
Allergic Respiratory Disease
There is substantial evidence that SCIT and SLIT are effective in reducing allergic 
symptoms in patients sensitized with allergic respiratory diseases, such as allergic rhinitis 
and asthma [3, 5]. A number of older studies have also found some persistent clinical 
benefits after AIT is stopped, which has been interpreted by some as evidence for tolerance 
induction. In a small double-blind study, Naclerio et al. evaluated the efficacy of SCIT in 
ragweed-allergic patients 1 year after therapy cessation [33]. Discontinuation of SCIT did 
not lead to worsening symptoms, but did result in increased nasal responses upon ragweed 
challenge. Durham and colleagues studied the long-term effects of grass pollen SCIT in 
small double-blinded, randomized, placebo-controlled trial [34]. Patients treated with SCIT 
for 3–4 years were randomized to either continue treatment or receive placebo injections for 
another 3 years. Discontinuation of AIT did not result in increased symptoms scores or 
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medication usage over the 3-year period. Patients in the discontinuation group did have a 
slight increase in allergen sensitivity as determined by skin-prick testing and conjunctival 
allergen challenge, but their reactivity was still significantly lower than that observed in a 
control group of patients who had never received AIT. Jacobsen et al. evaluated the long-
term clinical benefit of SCIT in 147 children with birch or grass pollen allergy [35]. After 10 
years, children who had received 3 years of SCIT had lower rates of asthma when compared 
to untreated patients (25 vs. 45 %, respectively), although bronchial responsiveness to 
methacholine did not vary between groups. SCIT patients also had slightly reduced 
conjunctival sensitivity (relative to baseline) 10 years after therapy.
More recently, Tabar et al. [36] performed a prospective study where patients with house 
dust mite (HDM) allergy were randomized to either 3 or 5 years of SCIT. At the end of 3 
years of therapy, both groups demonstrated similar improvement in asthma and rhinitis 
symptoms when compared to baseline. At the end of 5 years, overall clinical improvement 
was similar in the two groups. Two additional years of AIT further improved rhinitis 
symptoms, but not asthma symptoms or quality of life assessments. While objective 
measurements of clinical reactivity were not assessed, this study suggests that 3 years of 
therapy can induce some degree of clinical improvement for at least 2 years.
There have also been an increasing number of studies evaluating the sustained efficacy of 
SLIT for patients allergic to aeroallergens. In a randomized, double-blind, placebo-
controlled trial, Durham et al. [37, 38•] investigated the sustained efficacy of standardized 
grass pollen SLIT up to 2 years following the completion of 3 years of treatment. Compared 
to placebo, 3 years of SLIT resulted in a 29 and 40 % reduction in rhinoconjunctivitis 
symptoms scores and medication use, respectively [37]. Two years after discontinuing SLIT, 
rhinoconjunctivitis symptom scores remained significantly reduced by 25 % in the treatment 
group compared to the placebo group [38•]. Medication use was also decreased by 20 % in 
the treatment group, but this did not reach statistical significance. SLIT patients had 
sustained increases in serum levels of allergen-specific IgG4 and IgE-blocking factor at 2 
years following therapy. This is in contrast to a prior study of SCIT for grass pollen allergy 
[39], where allergen-specific IgG4 decreased after stopping therapy, suggesting that SCIT 
and SLIT may affect B cell responses differently.
Didier et al. evaluated the sustained efficacy of a 5-grass pollen sublingual tablet in 435 
participants enrolled in a randomized, double-blind, placebo-controlled trial. Treatment with 
the 5-grass tablet or placebo began either 2 or 4 months prior to the pollen season and was 
continued throughout the season. After 3 years, both treatment groups had significant 
improvements in adjusted rhinoconjunctivitis symptom scores when compared to placebo 
[40]. These improvements were maintained during the post-treatment pollen season, 
indicating that the treatment effect persisted for at least 1 year after therapy [41].
Recently, the sustained efficacy of SLIT for patients with HDM allergy was assessed in a 
large randomized, double-blind, placebo-controlled trial [42•]. Five hundred nine subjects 
were randomized to treatment with 300 index of reactivity (IR) tablets, 500 IR tablets or 
placebo for 12 months, after which therapy was stopped for 1 year. After 12 months of 
treatment, both tablets resulted in significant decreases of 18–20 % in average adjusted 
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symptom scores when compared to placebo. Importantly, these benefits persisted for up to 1 
year following therapy cessation. A limitation to these studies was that clinical reactivity 
was not assessed by pre- and post-treatment allergen challenges. In summary, SLIT for 
aeroallergen sensitivity appears to result in measurable clinical improvement for 1–2 years 
after therapy cessation.
Because SCIT and SLIT require treatment for several years before significant efficacy is 
observed, patient compliance is frequently problematic. Therefore, alternative 
immunotherapy strategies that expedite tolerance induction are being actively investigated. 
A recent study involving cat-allergic adults evaluated the efficacy of in-tradermal injections 
of synthetic peptides derived from the major cat allergen Fel d 1 [43]. The participants were 
randomized to placebo or one of two dosing regimens given over a 12-week period. 
Sustained efficacy was assessed in 89 subjects by aeroallergen challenge in an 
environmental exposure chamber. The authors found that a total of four monthly vaccine 
injections were sufficient to significantly reduce allergen-induced symptoms for up to 9 
months after therapy. Intralymphatic immunotherapy (ILIT) has also been proposed to 
induce more rapid clinical benefit compared to standard regimens of SCIT. In an open-label 
trial involving 165 grass pollen-allergic subjects, three intralymphatic allergen injections 
over 2 months resulted in sustained efficacy for up to 3 years as determined by nasal 
provocation testing [44]. In a small placebo-controlled trial [45], ILIT with modified Fel d 1 
improved nasal tolerance to cat allergen at 5 weeks following therapy; however, the study 
was not powered to assess long-term benefit. In contrast to these studies, a small randomized 
control trial evaluating 38 grass-allergic patients found no difference in symptom and 
medication scores between the ILIT or placebo groups [46]. Thus, the efficacy of this 
strategy remains to be fully determined.
Stinging Insect Allergy
Similar to food allergy, stinging insect allergy can be associated with severe and potentially 
fatal systemic reactions upon allergen exposure. Venom-allergic patients with a history of 
sting-induced anaphylaxis have a 30–60 % chance of developing systemic reactions upon 
subsequent stings [47]. Subcutaneous venom immunotherapy (VIT) is highly effective in 
desensitizing venom-allergic patients, as greater than 90 % of patients receiving therapy are 
protected from sting-induced anaphylaxis in several controlled trials [2]. Few studies have 
evaluated the long-term efficacy of VIT after discontinuing therapy, but those that have 
suggest that the great majority of patients remain protected against venominduced 
anaphylaxis. Golden and colleagues evaluated the incidence of sting-induced systemic 
reactions in adults who had completed 5 years of VIT [48]. Over a 4-year follow-up period, 
only 7 of 74 patients developed systemic symptoms when subjected to sting challenges after 
treatment cessation. A follow-up survey of this cohort found that about 85 % of patients 
remained protected from sting-induced anaphylaxis for up to 10 years after stopping VIT 
[49]. Lerch and Muller reported similar findings in a study of 200 patients who had received 
VIT for at least 3 years [50]. They found that during a period of 1–7 years after stopping 
therapy, only 12.5 % of patients' experienced systemic reactions upon subsequent stings.
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Children receiving VIT also appear to develop long-lasting protection. A survey of patients 
who received VIT during childhood found that only 5 % developed sting-induced systemic 
reactions over a 10- to 20-year period after stopping therapy [51]. More recently, Stritzke 
and Eng reported on the outcomes of 83 children undergoing VIT for a mean duration of 3.6 
years [52]. This retrospective study found that 15 % of honey bee allergic and 6 % of 
Vespula allergic patients developed systemic reactions upon subsequent stings. However, 
only 11 % of patients were stung while off of VIT, and the study was not powered for 
determining efficacy after therapy cessation.
Conclusions
There is growing evidence that AIT can result in significant and sustained clinical 
improvement for a number of patients suffering from allergic disorders. Recently, studies of 
OIT have suggested that clinical tolerance can be induced in a subset of food allergic 
patients. However, it is unclear if this state of tolerance is truly independent of regular 
consumption of the food, and therefore not merely a form of prolonged desensitization. In 
patients sensitized to aeroallergens, SCIT and SLIT can lead to decreased symptoms for 
several years after therapy cessation, but more objective evidence of tolerance induction is 
needed. VIT can provide long-term protection against sting-induced anaphylaxis, but how 
this sustained benefit relates to clinical tolerance requires more investigation. Overall, it 
remains to be determined if the clinical tolerance induced by AIT is equivalent to "true" 
tolerance—that is, a permanent state of clinical non-reactivity equivalent to that experienced 
by nonallergic individuals. Appropriately addressing this question will require long-term 
follow-up studies that incorporate objective methods for assessing clinical reactivity upon 
allergen challenge. Such studies will ultimately provide the necessary evidence for what can, 
and cannot, be attained with AIT.
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Table 1
Terminology used when describing tolerance
Term Description
Immunological tolerance • Unresponsiveness of the adaptive immune system to a specific antigen
• Involves deletion, inactivation (anergy) or suppression of antigen-specific lymphocytes
Clinical tolerance • A state of clinical non-reactivity to an allergen
• Generally considered permanent and independent of recurrent allergen exposure
• May be present in allergen-sensitized individuals
Natural tolerance • Clinical tolerance that develops as a result of natural exposure to allergens
• May occur as the initial response to an allergen, or develop spontaneously in previously allergic 
individuals
Induced tolerance (sustained 
unresponsiveness)
• Clinical tolerance that occurs in allergic subjects as a result of allergen immunotherapy
• May involve mechanisms that are distinct from those of natural tolerance
• Sustained unresponsiveness is used to describe persistent clinical non-reactivity in food allergy 
patients after successful immunotherapy
Desensitization • A temporary state of clinical non-reactivity that is dependent upon continuous exposure to allergen
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